Mitochondrial peptide

MOTS-c

A mitochondrial peptide that acts like exercise in a vial.

Emerging evidence

Overview

MOTS-c is a peptide encoded in mitochondrial DNA - not the cell's nucleus, which is unusual. It is released by mitochondria in response to metabolic stress and acts as a signaling molecule that improves how cells handle glucose and fat. The popular description - 'exercise in a vial' - comes from research showing it activates some of the same metabolic pathways that physical exercise does, including improved insulin sensitivity and metabolic flexibility. In practical terms, MOTS-c helps the body switch more readily between burning glucose and burning fat, which is a core feature of metabolic health. Its primary goals are energy, fat loss, and longevity support, with muscle support in a minor role. It is a good fit for people whose goals include more energy, fat loss (especially when metabolic inflexibility is a factor), and long-term cellular health. It stacks well with NAD+, SS-31, and 5-Amino-1MQ - a natural grouping of mitochondrial and metabolic support compounds. MOTS-c is delivered by subcutaneous injection, taken in the morning, 2 to 3 times per week. Dose range is 5 to 10 mg. Cycles run 4 to 8 weeks. It is generally well tolerated; flushing is a possible but mild side effect. MOTS-c is a research compound - not FDA-approved. Human data is emerging rather than established from large clinical trials. No pregnancy or cancer-history contraindications are listed in the current record. Exact dosing, injection schedule, and cycle structure are set with a licensed provider in the PepDepo network at consult.

At a glance

Route

SC injection

Dose

5-10 mg

Frequency

2-3x per week

Timing

Morning

Cycle

4-8 weeks

Combining

Stacks well with: NAD+, SS-31, 5-Amino-1MQ

Safety

Well tolerated; flushing possible.

Regulatory: Research compound.

Questions

What makes MOTS-c different from other energy peptides?⌄

It originates from mitochondrial DNA - the energy-producing organelles inside cells - rather than from classical peptide pathways. It improves insulin sensitivity and metabolic flexibility, meaning the body gets better at choosing the right fuel source at the right time.

How is it taken?⌄

Subcutaneous injection in the morning, 2 to 3 times per week. Dose range is 5 to 10 mg. Typical cycles are 4 to 8 weeks.

What goals does it support?⌄

Energy is its primary goal, followed by fat loss and longevity support, with a minor muscle-support role.

Are there any side effects?⌄

It is generally well tolerated. Flushing is listed as a possible side effect but tends to be mild.

Is it FDA-approved?⌄

No. MOTS-c is a research compound with emerging human data. It has not been through the FDA approval process.

What does it stack well with?⌄

MOTS-c is listed as compatible with NAD+, SS-31, and 5-Amino-1MQ - compounds that support mitochondrial function and cellular metabolism from complementary angles.

Related protocols

Recomp Timeless

Want a personalized protocol?

Exact dosing is set with a licensed provider in the PepDepo network. This page is education, not a prescription.

Book a consult

Education only, not medical advice. Peptides discussed are for informational purposes and many are not FDA-approved. Eligibility, prescribing, compounding, and dispensing are handled by appropriately licensed entities. Exact protocols and dosing are set with a licensed provider in the PepDepo network at consult. Content is pending clinical review.